CAMBRIDGE, Mass., April 2, 2026
Relay Therapeutics, Inc. announced that it will present initial clinical and preclinical data for zovegalisib (RLY-2608), a novel mutant-selective PI3Kα inhibitor, at the International Society for the Study of Vascular Anomalies (ISSVA) World Congress 2026 in Philadelphia. The upcoming presentation will highlight findings from early-stage clinical evaluation in patients with PIK3CA-driven vascular anomalies, representing a significant milestone in the development of precision medicine therapies targeting genetic diseases and oncology indications.
Early Clinical Data Highlights Precision Medicine Potential
The data to be presented will include clinical outcomes from approximately 20 efficacy-evaluable patients, offering initial insights into the safety, tolerability, and therapeutic activity of zovegalisib in both adult and pediatric populations. Zovegalisib is designed as a mutant-selective inhibitor of PI3Kα, a kinase frequently mutated in cancer and vascular anomalies, making it a critical target for precision oncology and rare disease treatment.
The trial’s inclusion of diverse patient populations reflects a broad clinical strategy aimed at addressing unmet medical needs across multiple indications, including genetic vascular malformations and metastatic breast cancer. These early findings are expected to provide foundational evidence supporting further clinical development and potential regulatory advancement.
Innovative Mechanism Targets PI3Kα Mutations with Precision
Advertisement
Zovegalisib represents a first-in-class allosteric, pan-mutant selective PI3Kα inhibitor, developed using Relay Therapeutics’ Dynamo® platform, which integrates computational modeling, structural biology, and molecular dynamics simulations. Unlike traditional PI3Kα inhibitors that target the orthosteric site and often result in off-target toxicity, zovegalisib is engineered to selectively inhibit mutant PI3Kα while sparing wild-type activity, thereby improving the therapeutic index and reducing adverse effects.
Preclinical data to be presented at the congress demonstrate that the compound can induce lesion regression with minimal hyperinsulinemia in murine models, further supporting its potential for improved safety and efficacy profiles. This targeted approach reflects the growing importance of precision drug design in overcoming limitations of conventional therapies.
Clinical Development Expands Across Oncology and Rare Diseases
Relay Therapeutics is actively advancing zovegalisib across multiple clinical programs, including a Phase 1/2 study in vascular anomalies and a Phase 3 trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. The drug’s ability to address PIK3CA-driven disease pathways positions it as a promising candidate for large patient populations, including approximately 170,000 individuals annually affected by vascular anomalies in the United States.
The dual application in oncology and genetic disorders underscores the versatility of the molecule and its potential to transform treatment paradigms. Additionally, the presentation at a major global scientific congress highlights the increasing importance of data transparency and peer-reviewed validation in drug development, aligning with Good Clinical Practice (GCP) standards and regulatory expectations.
Advancing Bio-Pharma Innovation Through Data-Driven Development
From a cGxP perspective, the development of zovegalisib reflects rigorous adherence to clinical research standards, regulatory compliance, and data integrity principles, ensuring that early findings are robust and reproducible. The integration of advanced computational drug discovery platforms with clinical validation represents a new frontier in biopharmaceutical innovation, enabling faster and more precise development of targeted therapies.
Relay Therapeutics’ approach demonstrates how cutting-edge science can translate into clinically meaningful outcomes, reinforcing the role of innovation-driven strategies in modern drug development. As additional data emerge, zovegalisib has the potential to become a key therapeutic option for patients with limited treatment alternatives, further advancing the field of precision medicine.
Source: Relay Therapeutics press release
